Glucocorticoids versus glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis with poor-prognosis factors.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sorin Boris, Papo Matthias, Sinico Renato A, Teixeira Vítor Silvestre, Venhoff Nils, Urban Maria-Letizia, Iudici Michele, Mahrhold Juliane, Locatelli Francesco, Cassone Giulia, Schiavon Franco, Seeliger Benjamin, Neumann Thomas, Feder Claudia, Kroegel Claus, Groh Matthieu, Marvisi Chiara, Samson Maxime, Barba Thomas, Jayne David, Troilo Arianna, Thiel Jens, Hellmich Bernhard, Monti Sara, Montecucco Carlomaurizio, Salvarani Carlo, Kahn Jean-Emmanuel, Bonnotte Bernard, Durel Cécile-Audrey, Puéchal Xavier, Mouthon Luc, Guillevin Loïc, Emmi Giacomo, Vaglio Augusto, Porcher Raphael, Terrier Benjamin
Аннотация
METHODS: We emulated a target trial using observational data from a European multicenter retrospective database. We included patients with newly diagnosed EGPA with a 1996 Five Factor Score (FFS) of at least 1, treated with GCs or GCs plus CYC between June 1985 and November 2018. Propensity score analysis was used to adjust for potential confounders. Primary outcome was relapse at 12months. Secondary outcomes included major relapse at 12months and GC-dependent asthma and/or ear nose and throat (ENT) manifestations at 24months.
RESULTS: A total of 209 patients were included: 47 % were male and the mean age at diagnosis was 52 (±16 years); 26 % were treated with GCs alone and 74 % with GCs plus CYC. After adjustment, the risk of relapse (hazard ratio [HR]: 0.24, 95%CI [0.08-0.67], p = 0.007), major relapse (HR: 0.24, 95%CI [0.07-0.85], p = 0.026) and the proportion of GC-dependent asthma and/or ENT manifestations (odds ratio:0.30, 95%CI [0.14-0.66], p = 0.003) were lower in the GCs plus CYC group compared to the GCs alone group.
CONCLUSION: This target trial emulation study shows that the addition of CYC to GCs reduces the risk of vasculitis relapse and the rate of GC-dependent asthma and/or ENT manifestations in patients with poor-prognosis EGPA.